Literature DB >> 9275031

Stromal tenascin distribution as a prognostic marker in colorectal cancer.

U Kressner1, G Lindmark, B Tomasini-Johansson, R Bergström, B Gerdin, L Påhlman, B Glimelius.   

Abstract

A total of 169 colorectal adenocarcinomas, obtained from patients with a median follow-up of 6.5 years, were studied with immunohistochemical staining on cryosections using a monoclonal anti-tenascin antibody to evaluate the possible association between the staining patterns and tumour stage, tumour differentiation and survival. We found two different staining patterns in the tumour stroma--a diffuse stromal fibrillar staining in 92 out of 169 (54%) tumours and a subglandular staining in the remaining 77 tumours. When the entire group of patients (P < 0.01) and the group of potentially cured patients (P < 0.03) were analysed univariately, it was found that diffuse stromal fibrillar staining was associated with a shorter survival time than subglandular staining. In a multivariate analysis, the Dukes' stage and age were independent prognostic factors, whereas the tenascin expression did not retain a clear independent relationship to survival (P = 0.06). Hence, it appears that the tumour expression of tenascin may be a potential prognostic marker in colorectal cancer, in so far as a diffuse stromal fibrillar staining pattern seems to indicate an increased risk of poor outcome. However, after adjustment for age and Dukes' stage, the additional prognostic value of tenascin remains to be established in further analyses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9275031      PMCID: PMC2227978          DOI: 10.1038/bjc.1997.419

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis.

Authors:  I Sugawara; J Hirakoshi; A Masunaga; S Itoyama; T Sakakura
Journal:  Invasion Metastasis       Date:  1991

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

Review 3.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors.

Authors:  H P Erickson; M A Bourdon
Journal:  Annu Rev Cell Biol       Date:  1989

Review 4.  Tenascin: a hexameric adhesive glycoprotein.

Authors:  P G Natali; L Zardi
Journal:  Int J Cancer Suppl       Date:  1989

5.  A new prognostic classification of rectal cancer.

Authors:  J R Jass; S B Love; J M Northover
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

6.  Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma.

Authors:  S E Riedl; A Faissner; P Schlag; A Von Herbay; K Koretz; P Möller
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

7.  Preoperative serum markers in carcinoma of the rectum and rectosigmoid. I. Prediction of tumour stage.

Authors:  E Ståhle; B Glimelius; R Bergström; L Påhlman
Journal:  Eur J Surg Oncol       Date:  1988-08       Impact factor: 4.424

8.  Heterogeneity in ploidy and S-phase fraction in colorectal adenocarcinomas.

Authors:  G Lindmark; B Glimelius; L Påhlman; P Enblad
Journal:  Int J Colorectal Dis       Date:  1991-05       Impact factor: 2.571

Review 9.  Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions.

Authors:  P Ekblom; E Aufderheide
Journal:  Int J Dev Biol       Date:  1989-03       Impact factor: 2.203

10.  Induction of tenascin in healing wounds.

Authors:  E J Mackie; W Halfter; D Liverani
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  8 in total

1.  A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.

Authors:  Seetharaman Balasenthil; Nanyue Chen; Steven T Lott; Jinyun Chen; Jennifer Carter; William E Grizzle; Marsha L Frazier; Subrata Sen; Ann McNeill Killary
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Tenascin immunoreactivity in the large bowel and the liver in patients with colorectal cancer.

Authors:  M V Gulubova; T Vlaykova
Journal:  Histochem J       Date:  2001-02

3.  Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer.

Authors:  Akihiko Takeda; Yoshihide Otani; Hiroyoshi Iseki; Hideki Takeuchi; Kimiyasu Aikawa; Satoru Tabuchi; Nozomi Shinozuka; Toshiaki Saeki; Yasushi Okazaki; Isamu Koyama
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

4.  Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation.

Authors:  A Juuti; S Nordling; J Louhimo; J Lundin; C Haglund
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

5.  Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer.

Authors:  A Brunner; C Mayerl; A Tzankov; I Verdorfer; I Tschörner; H Rogatsch; G Mikuz
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

6.  The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways.

Authors:  Petra A Tsuji; Bradley A Carlson; Min-Hyuk Yoo; Salvador Naranjo-Suarez; Xue-Ming Xu; Yiwen He; Esther Asaki; Harold E Seifried; William C Reinhold; Cindy D Davis; Vadim N Gladyshev; Dolph L Hatfield
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

7.  Clustering gene expression regulators: new approach to disease subtyping.

Authors:  Mikhail Pyatnitskiy; Ilya Mazo; Maria Shkrob; Elena Schwartz; Ekaterina Kotelnikova
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

8.  Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer.

Authors:  Christopher R Silvers; Edward M Messing; Hiroshi Miyamoto; Yi-Fen Lee
Journal:  Br J Cancer       Date:  2021-09-25       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.